An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

BACKGROUND: Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclinical models of triple-negative breast cancer (TNBC) with intact DNA repair,...

Descripción completa

Detalles Bibliográficos
Autores principales: Stringer-Reasor, Erica M., May, Jori E., Olariu, Eva, Caterinicchia, Valerie, Li, Yufeng, Chen, Dongquan, Della Manna, Deborah L., Rocque, Gabrielle B., Vaklavas, Christos, Falkson, Carla I., Nabell, Lisle M., Acosta, Edward P., Forero-Torres, Andres, Yang, Eddy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934554/
https://www.ncbi.nlm.nih.gov/pubmed/33663560
http://dx.doi.org/10.1186/s13058-021-01408-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934554/
https://www.ncbi.nlm.nih.gov/pubmed/33663560
http://dx.doi.org/10.1186/s13058-021-01408-9

Ejemplares similares